bioRxivNeurosciencePreprint
A reproducibility-audit framework for generalizable versus dataset-specific molecular transition boundaries in Alzheimer's disease
YoungOuk KimiD, WooMyung HeoiD, Se Jin ParkiD, YoungChul Kim, Ye Eun Cho
Abstract
Molecular staging of Alzheimer's disease (AD) increasingly defines transition boundaries along single-cell pseudo-progression trajectories, yet whether such boundaries reproduce across brain regions, cohorts and molecular modalities is rarely tested. We present a permutation-controlled audit that combines nine boundary-detection algorithms with a fixed marker panel and four orthogonal reproducibility axes-algorithmic consensus, region, cohort and modality. On synthetic data with planted ground-truth boundaries the audit reaches 100% sensitivity and 94% specificity, rejecting four distinct artefact classes each by a different axis. Applied to the Seattle Alzheimer's Disease Brain Cell Atlas middle temporal gyrus, it localizes a transition that is robust across algorithms and recovered in most cell types but does not generalize: its leading marker is attenuated or absent in prefrontal cortex, entorhinal cortex and cerebrospinal fluid, and an apparent cross-region conservation of glial metabolic genes proves to be a global-expression offset rather than a shared program. The same audit nonetheless certifies an externally validated marker (astrocytic PTGDS) as reproducible across regions and modalities, showing that it separates generalizable anchors from dataset-specific ones rather than rejecting all signals. We provide this four-axis audit as a transferable, code-available standard to apply before a trajectory boundary is read as a biological stage, in AD and other progressive proteinopathies.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pseudotime analysis of 2,106 brains across nine regions reveals conserved immune, neuronal, and myelin regulatory programs in Alzheimer's disease
Fabrizio Ecca, Serena Song, … Ignazio Stefano Piras·bioRxiv·Aug 23, 2026
- Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer disease progression that reinforces the 2018 NIA-AA research framework
Priya Devanarayan, Viswanath Devanarayan, … the Alzheimer’s Disease Neuroimaging Initiative (ADNI)·Journal of Alzheimer s DiseasePeer-reviewed·Feb 12, 2019
- Reproducible evaluation of classification methods in Alzheimer’s disease: framework and application to MRI and PET data
Jorge Samper‐Gonzàlez, Ninon Burgos, … the Australian Imaging Biomarkers and Lifestyle flagship study of ageing2·bioRxiv·Apr 6, 2018
- Rapid Mechanistic Bridging of an Alzheimer's Disease Plasma Protein Staging Panel Across Brain Proteomics Cohorts
Charles C. Kim, Meghan Kerrisk Campbell, … Peter Cimermančič·bioRxiv·Sep 4, 2026
- Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease
Julie K. Wisch, Ziqiao Jiao, … Laura Ibáñez·bioRxiv·Jul 13, 2026
- Multidomain Analysis of Clinical Cognitive Assessments and Imaging Data in Alzheimer's Disease Accurately Predicts Disease Stage and Grade Independent of Amyloid and Tau
Juan Antonio K. Chong Chie, Scott A. Persohn, … Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Apr 13, 2026